Estrella Immunopharma, Inc. (ESLA) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Estrella Immunopharma, Inc. (ESLA) Earnings Overview
As of June 30, 2026, Estrella Immunopharma, Inc. (ESLA) reported trailing twelve-month net income of -$13M, reflecting -40.0% year-over-year growth. The company earned $-0.31 per diluted share over the past four quarters.
Looking at the long-term picture, ESLA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$996,104 in fiscal 2022.
Estrella Immunopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), CRIS (-$21M net income, -80.3% margin), IMVT (-$506M net income), ESLA has comparable earnings metrics. Compare ESLA vs FATE →
ESLA Earnings vs Peers
Earnings metrics vs comparable public companies
ESLA Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$13M | -47.6% | -$13M | $-0.35 | - | - |
| 2024 | -$9M | -21.0% | -$9M | $-0.25 | - | - |
| 2023 | -$7M | -634.0% | -$7M | $-0.21 | - | - |
| 2022 | $-996,104 | +40.9% | -$2M | $-0.17 | - | - |
| 2021 | -$2M | - | -$2M | $-0.29 | - | - |
Download Data
Export ESLA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ESLA — Frequently Asked Questions
Quick answers to the most common questions about buying ESLA stock.
What is ESLA earnings per share (EPS)?
ESLA trailing twelve-month (TTM) diluted EPS is $-0.31, reflecting -40.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Estrella Immunopharma, Inc.'s net income?
Estrella Immunopharma, Inc. (ESLA) trailing twelve-month net income is $-13M as of 2025. Earnings declined -40.0% year-over-year.
Is ESLA profitable?
ESLA is not currently profitable on a TTM basis, reporting a net loss of $-13M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ESLA's earnings growth rate?
ESLA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are ESLA's profit margins?
Estrella Immunopharma, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is ESLA growing earnings?
ESLA earnings are declining — EPS fell -40.0% year-over-year. TTM net income dropped to $-13M. This contrasts with the 5-year CAGR of N/A.
What was ESLA's best earnings year?
Estrella Immunopharma, Inc.'s highest annual net income on record is $-996104.00, achieved in fiscal year 2022. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were ESLA's earnings last quarter?
ESLA's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.05. For a full breakdown of all quarters, see the quarterly earnings table on this page.